Cargando…
Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment
There are limited reports regarding early predictors of objective response (OR) in patients with hepatocellular carcinoma (HCC) treated with lenvatinib. This retrospective study including 70 patients aimed to investigate the efficacy of hepatic biochemical markers. Changes in tumor marker (alpha-fet...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225985/ https://www.ncbi.nlm.nih.gov/pubmed/32218295 http://dx.doi.org/10.3390/cancers12040779 |
_version_ | 1783534181057298432 |
---|---|
author | Saeki, Issei Yamasaki, Takahiro Yamashita, Satoyoshi Hanazono, Tadasuke Urata, Yohei Furutani, Takakazu Yokoyama, Yuichiro Oishi, Toshiyuki Maeda, Masaki Kimura, Teruaki Kotoh, Yurika Sasaki, Ryo Miyaji, Takashi Oono, Takashi Aibe, Yuki Hisanaga, Takuro Iwamoto, Takuya Matsumoto, Toshihiko Hidaka, Isao Ishikawa, Tsuyoshi Takami, Taro Sakaida, Isao |
author_facet | Saeki, Issei Yamasaki, Takahiro Yamashita, Satoyoshi Hanazono, Tadasuke Urata, Yohei Furutani, Takakazu Yokoyama, Yuichiro Oishi, Toshiyuki Maeda, Masaki Kimura, Teruaki Kotoh, Yurika Sasaki, Ryo Miyaji, Takashi Oono, Takashi Aibe, Yuki Hisanaga, Takuro Iwamoto, Takuya Matsumoto, Toshihiko Hidaka, Isao Ishikawa, Tsuyoshi Takami, Taro Sakaida, Isao |
author_sort | Saeki, Issei |
collection | PubMed |
description | There are limited reports regarding early predictors of objective response (OR) in patients with hepatocellular carcinoma (HCC) treated with lenvatinib. This retrospective study including 70 patients aimed to investigate the efficacy of hepatic biochemical markers. Changes in tumor marker (alpha-fetoprotein (AFP)/des-gamma-carboxy prothrombin (DCP)) levels and albumin–bilirubin (ALBI) score between the baseline value and that estimated one month after treatment were evaluated. We identified several predictors of OR, including changes in tumor marker levels. The OR rate calculated using modified Response Evaluation Criteria in Solid Tumor (mRECIST) was 41.4%. Response was defined as a reduction in AFP and DCP levels of ≥40% from baseline. OR was significantly associated with AFP response, but not with DCP. Predictors of OR were evaluated in two groups (high-AFP group: baseline AFP ≥ 10 ng/mL; low-AFP group: remaining patients). A multivariate analysis identified AFP response (odds ratio, 51.389; p = 0.001) and ALBI score (odds ratio, 6.866; p = 0.039) as independent predictors of OR in the high-AFP and low-AFP groups, respectively. Changes in the ALBI score indicated deterioration in both responders and non-responders, with a significant difference in non-responders (p = 0.003). AFP response, baseline ALBI score, and change in the ALBI score were early predictors of OR in patients with HCC undergoing lenvatinib treatment. |
format | Online Article Text |
id | pubmed-7225985 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-72259852020-05-18 Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment Saeki, Issei Yamasaki, Takahiro Yamashita, Satoyoshi Hanazono, Tadasuke Urata, Yohei Furutani, Takakazu Yokoyama, Yuichiro Oishi, Toshiyuki Maeda, Masaki Kimura, Teruaki Kotoh, Yurika Sasaki, Ryo Miyaji, Takashi Oono, Takashi Aibe, Yuki Hisanaga, Takuro Iwamoto, Takuya Matsumoto, Toshihiko Hidaka, Isao Ishikawa, Tsuyoshi Takami, Taro Sakaida, Isao Cancers (Basel) Article There are limited reports regarding early predictors of objective response (OR) in patients with hepatocellular carcinoma (HCC) treated with lenvatinib. This retrospective study including 70 patients aimed to investigate the efficacy of hepatic biochemical markers. Changes in tumor marker (alpha-fetoprotein (AFP)/des-gamma-carboxy prothrombin (DCP)) levels and albumin–bilirubin (ALBI) score between the baseline value and that estimated one month after treatment were evaluated. We identified several predictors of OR, including changes in tumor marker levels. The OR rate calculated using modified Response Evaluation Criteria in Solid Tumor (mRECIST) was 41.4%. Response was defined as a reduction in AFP and DCP levels of ≥40% from baseline. OR was significantly associated with AFP response, but not with DCP. Predictors of OR were evaluated in two groups (high-AFP group: baseline AFP ≥ 10 ng/mL; low-AFP group: remaining patients). A multivariate analysis identified AFP response (odds ratio, 51.389; p = 0.001) and ALBI score (odds ratio, 6.866; p = 0.039) as independent predictors of OR in the high-AFP and low-AFP groups, respectively. Changes in the ALBI score indicated deterioration in both responders and non-responders, with a significant difference in non-responders (p = 0.003). AFP response, baseline ALBI score, and change in the ALBI score were early predictors of OR in patients with HCC undergoing lenvatinib treatment. MDPI 2020-03-25 /pmc/articles/PMC7225985/ /pubmed/32218295 http://dx.doi.org/10.3390/cancers12040779 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Saeki, Issei Yamasaki, Takahiro Yamashita, Satoyoshi Hanazono, Tadasuke Urata, Yohei Furutani, Takakazu Yokoyama, Yuichiro Oishi, Toshiyuki Maeda, Masaki Kimura, Teruaki Kotoh, Yurika Sasaki, Ryo Miyaji, Takashi Oono, Takashi Aibe, Yuki Hisanaga, Takuro Iwamoto, Takuya Matsumoto, Toshihiko Hidaka, Isao Ishikawa, Tsuyoshi Takami, Taro Sakaida, Isao Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment |
title | Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment |
title_full | Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment |
title_fullStr | Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment |
title_full_unstemmed | Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment |
title_short | Early Predictors of Objective Response in Patients with Hepatocellular Carcinoma Undergoing Lenvatinib Treatment |
title_sort | early predictors of objective response in patients with hepatocellular carcinoma undergoing lenvatinib treatment |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225985/ https://www.ncbi.nlm.nih.gov/pubmed/32218295 http://dx.doi.org/10.3390/cancers12040779 |
work_keys_str_mv | AT saekiissei earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT yamasakitakahiro earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT yamashitasatoyoshi earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT hanazonotadasuke earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT uratayohei earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT furutanitakakazu earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT yokoyamayuichiro earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT oishitoshiyuki earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT maedamasaki earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT kimurateruaki earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT kotohyurika earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT sasakiryo earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT miyajitakashi earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT oonotakashi earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT aibeyuki earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT hisanagatakuro earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT iwamototakuya earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT matsumototoshihiko earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT hidakaisao earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT ishikawatsuyoshi earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT takamitaro earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment AT sakaidaisao earlypredictorsofobjectiveresponseinpatientswithhepatocellularcarcinomaundergoinglenvatinibtreatment |